Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer
- Author(s)
- Veneziani, AC; Scott, C; Wakefield, MJ; Tinker, AV; Lheureux, S;
- Journal Title
- Therapeutic Advances in Medical Oncology
- Publication Type
- Review
- Abstract
- Poly (ADP-ribose) polymerase inhibitors (PARPis) represent a therapeutic milestone in the management of epithelial ovarian cancer. The concept of 'synthetic lethality' is exploited by PARPi in tumors with defects in DNA repair pathways, particularly homologous recombination deficiency. The use of PARPis has been increasing since its approval as maintenance therapy, particularly in the first-line setting. Therefore, resistance to PARPi is an emerging issue in clinical practice. It brings an urgent need to elucidate and identify the mechanisms of PARPi resistance. Ongoing studies address this challenge and investigate potential therapeutic strategies to prevent, overcome, or re-sensitize tumor cells to PARPi. This review aims to summarize the mechanisms of resistance to PARPi, discuss emerging strategies to treat patients post-PARPi progression, and discuss potential biomarkers of resistance.
- Publisher
- Sage
- Department(s)
- Medical Oncology
- PubMed ID
- 36872947
- Publisher's Version
- https://doi.org/10.1177/17588359231157644
- Open Access at Publisher's Site
https://doi.org/10.1177/17588359231157644- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-06-15 07:24:51
Last Modified: 2023-06-15 07:25:48